Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Trypanosoma brucei gambiense | vacuolar-type proton translocating pyrophosphatase 1, putative | References | |
Trypanosoma brucei | Pyrophosphate-energized vacuolar membrane proton pump 1 | Starlite/ChEMBL | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium falciparum | V-type K+-independent H+-translocating inorganic pyrophosphatase | 0.0542081 | 0.5 | 0.5 |
Toxoplasma gondii | V-type H(+)-translocating pyrophosphatase VP1 | 0.0542081 | 0.5 | 0.5 |
Trypanosoma cruzi | Vacuolar proton pyrophosphatase 1, putative | 0.0542081 | 0.5 | 0.5 |
Plasmodium vivax | vacuolar-type H+ pumping pyrophosphatase, putative | 0.0542081 | 0.5 | 0.5 |
Leishmania major | vacuolar-type proton translocating pyrophosphatase 1, putative | 0.0542081 | 0.5 | 0.5 |
Plasmodium falciparum | V-type H(+)-translocating pyrophosphatase, putative | 0.0542081 | 0.5 | 0.5 |
Plasmodium vivax | V-type H(+)-translocating pyrophosphatase, putative | 0.0542081 | 0.5 | 0.5 |
Trypanosoma brucei | Pyrophosphate-energized vacuolar membrane proton pump 2, putative | 0.0542081 | 0.5 | 0.5 |
Trypanosoma brucei | Pyrophosphate-energized vacuolar membrane proton pump 1 | 0.0542081 | 0.5 | 0.5 |
Trypanosoma cruzi | vacuolar-type proton translocating pyrophosphatase 1 | 0.0542081 | 0.5 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED50 (functional) | = 283 uM | Dose of the compound to inhibit the growth of human KB carcinoma cell line | ChEMBL. | 16162013 |
ED50 (functional) | = 283 uM | Dose of the compound to inhibit the growth of human KB carcinoma cell line | ChEMBL. | 16162013 |
IC50 (functional) | = 5.4 | Growth inhibition of Plasmodium falciparum | ChEMBL. | 19053772 |
IC50 (functional) | = 4.3 uM | Growth inhibition of Plasmodium falciparum | ChEMBL. | 19053772 |
IC50 (binding) | = 7.5 uM | Inhibition of recombinant trypanosoma brucei soluble vacuolar pyrophosphatase expressed in escherichia coli | ChEMBL. | 16162013 |
IC50 (binding) | = 7.5 uM | Inhibition of recombinant trypanosoma brucei soluble vacuolar pyrophosphatase expressed in escherichia coli | ChEMBL. | 16162013 |
IZ (functional) | = 0 mm | Antibacterial activity against Escherichia coli pTMV19 in presence of mevalonate | ChEMBL. | 17149863 |
IZ (functional) | = 0 mm | Antibacterial activity against Escherichia coli pTMV19 in presence of mevalonate | ChEMBL. | 17149863 |
IZ (functional) | = 8 mm | Antibacterial activity against Escherichia coli W3110 | ChEMBL. | 17149863 |
IZ (functional) | = 8 mm | Antibacterial activity against Escherichia coli W3110 | ChEMBL. | 17149863 |
IZ (functional) | = 11 mm | Antibacterial activity against Escherichia coli pTMV19 | ChEMBL. | 17149863 |
IZ (functional) | = 11 mm | Antibacterial activity against Escherichia coli pTMV19 | ChEMBL. | 17149863 |
TI (functional) | = 38 | Ratio of ED50 against KB cell line to that of IC50 of TbVSP1 | ChEMBL. | 16162013 |
TI (functional) | = 38 | Ratio of ED50 against KB cell line to that of IC50 of TbVSP1 | ChEMBL. | 16162013 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 | 19053772 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.